Targeting factor XIIa for therapeutic interference with hereditary angioedema

Area of Science:

• Immunology
• Genetics
• Pharmacology

Background:

• Hereditary angioedema (HAE) is a rare genetic disorder causing recurrent swelling attacks.
• Bradykinin overproduction, driven by the FXIIa-kallikrein-kinin system, underlies HAE pathogenesis.
• Current HAE therapies require improvement in efficacy, quality of life, and treatment burden.

Purpose of the Study:

• To review the potential of targeting activated factor XII (FXIIa) for HAE pharmacologic interference.
• To provide an overview of FXIIa inhibitors in development for HAE and other conditions.
• To summarize clinical trial evidence for garadacimab as a novel HAE prophylactic treatment.

Main Methods:

• Review of preclinical, experimental animal, and in vitro studies on FXIIa inhibition.
• Analysis of clinical trial data for garadacimab in HAE patients.
• Discussion of FXIIa's therapeutic potential beyond HAE.

Main Results:

• Activated factor XII (FXIIa) is a viable therapeutic target for HAE.
• Garadacimab, an FXIIa-inhibiting monoclonal antibody, is the most advanced FXIIa inhibitor.
• Clinical trials indicate garadacimab's potential as a long-term prophylactic treatment for HAE.

Conclusions:

• Targeting FXIIa offers a promising strategy for novel HAE treatments.
• Garadacimab demonstrates significant potential for long-term HAE prophylaxis.
• Further research into FXIIa inhibition may reveal therapeutic applications beyond HAE.